이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

크론병 관리 및 치료에 도움이 되는 CDPATH™ 연구 (COMPASS-CD)

2026년 10월 5일 업데이트: Takeda

크론병 위험 예측 도구인 CDPATH™의 실제 사용을 평가하는 4상 연구

CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.

The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.

연구 유형

중재적

등록 (실제)

241

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Arizona
      • Phoenix, Arizona, 미국, 85032
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Loma Linda, California, 미국, 92357
        • VA Loma Linda Healthcare System
      • Murrieta, California, 미국, 92563
        • United Medical Doctors
      • Newport Beach, California, 미국, 92663
        • University of Southern California Medical Center
      • Orange, California, 미국, 92868
        • University of California at Irvine Medical Center
      • Orange, California, 미국, 92868
        • Clinnova Research Solutions
    • Colorado
      • Aurora, Colorado, 미국, 80014
        • Kaiser Permanate of Colorado
    • Connecticut
      • Hamden, Connecticut, 미국, 06518
        • Medical Research Center of Connecticut, LLC
    • Florida
      • Clearwater, Florida, 미국, 33762
        • West Central Gastroenterology d/b/a Gastro Florida
      • Pensacola, Florida, 미국, 32503
        • Gastroenterology Associates of Pensacola, PA
    • Idaho
      • Idaho Falls, Idaho, 미국, 83404
        • Grand Teton Research Group, PLL
    • Illinois
      • Arlington Heights, Illinois, 미국, 60005
        • GI Alliance
      • Gurnee, Illinois, 미국, 60031
        • GI Alliance
      • Northbrook, Illinois, 미국, 60062
        • Comprehensive Gastrointestinal Health
      • Rockford, Illinois, 미국, 61107
        • Rockford Gastroenterology Associates, Ltd.
    • Indiana
      • Indianapolis, Indiana, 미국, 46202
        • Indiana University
    • Iowa
      • Clive, Iowa, 미국, 50325
        • Iowa Digestive Disease Center
      • Iowa City, Iowa, 미국, 52242-1009
        • University of Iowa Hospitals & Clinics
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • University of Kansas Medical Center Research Institute, Inc.
    • Louisiana
      • Baton Rouge, Louisiana, 미국, 70809
        • GI Alliance - Baton Rouge
      • Shreveport, Louisiana, 미국, 71105
        • Louisiana Research Center, LLC
    • Maryland
      • Columbia, Maryland, 미국, 21045
        • Gastro Center of Maryland
    • Massachusetts
      • Burlington, Massachusetts, 미국, 01805
        • Lahey Clinic Inc. - PARENT ACCOUNT
      • Worcester, Massachusetts, 미국, 01655
        • UMASS Memorial Medical Center
    • New Mexico
      • Albuquerque, New Mexico, 미국, 87131-0001
        • University of New Mexico
    • New York
      • New York, New York, 미국, 10075-1850
        • Lenox Hill Hospital
    • Ohio
      • Beavercreek, Ohio, 미국, 45431
        • Clinical Inquest Center Ltd
      • Dayton, Ohio, 미국, 45415
        • Dayton Gastroenterology, Inc
    • Oregon
      • Portland, Oregon, 미국, 97220-9442
        • The Oregon Clinic, P.C.
    • Pennsylvania
      • Camp Hill, Pennsylvania, 미국, 17011
        • Susquehanna Research Group, LLC
      • Pittsburgh, Pennsylvania, 미국, 15213
        • University of Pittsburgh Medical Center Health System
      • Pittsburgh, Pennsylvania, 미국, 15212
        • Allegheny Center for Digestive Health
      • Uniontown, Pennsylvania, 미국, 15401
        • Frontier Clinical Research, LLC
    • South Carolina
      • Summerville, South Carolina, 미국, 29486
        • Palmetto Primary Care Physician Division of Gastroenterology
    • South Dakota
      • Rapid City, South Dakota, 미국, 57701
        • Rapid City Medical Center, LLC
    • Tennessee
      • Nashville, Tennessee, 미국, 37204
        • Vanderbilt University Medical Center
    • Texas
      • Austin, Texas, 미국, 78712
        • The University of Texas at Austin
      • Houston, Texas, 미국, 77030
        • Baylor College of Medicine
      • Southlake, Texas, 미국, 76092
        • GI Alliance - Southlake
    • Utah
      • Ogden, Utah, 미국, 84403
        • Care Access Research Berkley
      • Salt Lake City, Utah, 미국, 84132
        • University of Utah
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • GCGA Physicians LLC
      • Lynchburg, Virginia, 미국, 24502
        • Gastroenterology Associates
    • Washington
      • Bellevue, Washington, 미국, 98405
        • GI Alliance

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
  2. Has agreed to use the CDPATH™ tool.
  3. Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.

Exclusion Criteria:

  1. Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
  2. Has had any non-CD-related abdominal surgery.
  3. Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
  4. Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 특수 증상
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: CDPATH™

Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis.

Crohn's disease risk prediction tool.

다른 이름들:
  • 전망

Three blood samples will be drawn.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results
기간: Baseline (Day 1)

The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years.

Baseline (Day 1)

2차 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category
기간: Up to 36 months

Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification.

Up to 36 months
Change From Baseline in Decisional Conflict Scale (DCS) Score
기간: Baseline, then every 6 months up to 36 months

DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict.

Baseline, then every 6 months up to 36 months
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score
기간: Baseline, then every 6 months up to 36 months

WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity).

Baseline, then every 6 months up to 36 months
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score
기간: Baseline, then every 6 months up to 36 months

PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health).

Baseline, then every 6 months up to 36 months
Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool
기간: Up to 36 months

Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool.

Up to 36 months
Number of Participants with Clinical Outcomes
기간: Up to 36 months

Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported.

Up to 36 months
Percentage of Participants with Healthcare Resource Utilization
기간: Up to 36 months

Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.).

Up to 36 months
Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool
기간: First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability.

First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Study Director, Takeda

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 6월 25일

기본 완료 (실제)

2026년 8월 27일

연구 완료 (실제)

2026년 8월 27일

연구 등록 날짜

최초 제출

2021년 3월 19일

QC 기준을 충족하는 최초 제출

2021년 3월 19일

처음 게시됨 (실제)

2021년 3월 22일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 8일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 5일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

키워드

기타 연구 ID 번호

  • Vedolizumab-4015

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD 공유 액세스 기준

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .